http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0603335-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 1992-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c9f75b9e2f0895fa549fb868b660dfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9378b2e1788ba763ded32ad99c2befea |
| publicationDate | 1994-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0603335-A1 |
| titleOfInvention | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
| abstract | A method of alleviating the symptoms of the drug withdrawal reaction in a human or animal is to administer to the subject an effective amount of the symptom of the drug withdrawal reaction symptom, which amount consists of an inhibitor nitric oxide synthase (SON) for an effective period of time in order to alleviate such symptoms of reaction to drug withdrawal. SON inhibitors useful in this method include, for example L-NG-nitroarginine, L-NG-nitroarginine esters, L-NG-monomethylarginine, L-NG-benzylarginine, L-NG-aminoarginine, iminoethylornitine and their pharmaceutically acceptable salts . These compounds can be used alone or in combination, in conjunction with conventional drugs, such as alpha2-adrenoceptor agonists, mixed agonist-antagonist opiates and NMDA antagonists to reduce symptoms of the reaction to drug withdrawal. Effective doses of SON inhibitors range from approximately 1 mug / kg / day to approximately 30 mg / kg / day, administered over a period of approximately one hour to approximately six days following the reaction to opioid withdrawal. |
| priorityDate | 1991-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.